FBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Fortress Biotech is: High Risk: High uncertainty.
For the Biotechnology subindustry, Fortress Biotech's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Risk Assessment falls into.
Fortress Biotech (NAS:FBIO) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Fortress Biotech's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosenwald Lindsay A Md | director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 375 PARK AVE, NEW YORK NY 10152 |
Lucy Lu | director | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
David Jin | officer: Chief Financial Officer | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Dov Klein | director | C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
Robyn Hunter | officer: Chief Financial Officer | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Malcolm Hoenlein | director | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Michael S Weiss | director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN | 750 LEXINGTON AVE, NEW YORK NY 10022 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Jimmie Harvey | director | 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213 |
Kevin Lorenz | director | C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606 |
George Avgerinos | officer: SVP, Biologics Operations | C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Kevin Horgan | other: Former Chief Medical Officer | C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540 |
David Jonathan Barrett | director | ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
From GuruFocus
By sperokesalga sperokesalga • 02-16-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
By GuruFocusNews GuruFocusNews • 06-17-2022
By PRNewswire • 12-04-2023
By Value_Insider Value_Insider • 12-19-2022
By GuruFocus Research • 11-17-2023
By PurpleRose PurpleRose • 08-11-2022
By Marketwired • 08-03-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.